CLOV
Clover Health Investments Corp
$
3.035
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.100
Open
3.080
VWAP
3.04
Vol
6.23M
Mkt Cap
1.54B
Low
3.010
Amount
18.94M
EV/EBITDA(TTM)
--
Total Shares
496.44M
EV
1.38B
EV/OCF(TTM)
42.99
P/S(TTM)
1.01
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
464.99M
+38%
--
--
466.94M
+41.08%
--
--
468.30M
+31.45%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Clover Health Investments, Corp. (CLOV) for FY2025, with the revenue forecasts being adjusted by -0.02% over the past three months. During the same period, the stock price has changed by -12.54%.
Revenue Estimates for FY2025
Revise Downward
-0.02%
In Past 3 Month
Stock Price
Go Down
-12.54%
In Past 3 Month
3 Analyst Rating
56.51% Upside
Wall Street analysts forecast CLOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLOV is 4.75 USD with a low forecast of 3.75 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
56.51% Upside
Current: 3.035
Low
3.75
Averages
4.75
High
6.00
56.51% Upside
Current: 3.035
Low
3.75
Averages
4.75
High
6.00
Canaccord Genuity
Richard Close
Strong Buy
Maintains
$4.2 → $4.5
2025-03-03
Reason
Canaccord Genuity
Richard Close
Price Target
$4.2 → $4.5
2025-03-03
Maintains
Strong Buy
Reason
Craig-Hallum
Matt Hewitt
Strong Buy
Initiates
$6
2024-12-17
Reason
Craig-Hallum
Matt Hewitt
Price Target
$6
2024-12-17
Initiates
Strong Buy
Reason
Craig-Hallum analyst Matt Hewitt initiated coverage of Clover Health with a Buy rating and $6 price target.
UBS
Jonathan Yong
Hold
Initiates
$4
2024-10-07
Reason
UBS
Jonathan Yong
Price Target
$4
2024-10-07
Initiates
Hold
Reason
UBS initiated coverage of Clover Health with a Neutral rating and $4 price target. Clover Health has done a good job improving its core operations and medical costs, and the improved Star rating of 3.5, based on preliminary Planfinder data, also gives increasing confidence on improving Medicare Advantage enrollment growth and overall top-line growth, which will allow Clover to accelerate growth while maintaining reasonable economics, the analyst tells investors in a research note. However, the firm sees all this as appropriately captured in the stock price.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Clover Health Investments Corp (CLOV.O) is -22.30, compared to its 5-year average forward P/E of -9.47. For a more detailed relative valuation and DCF analysis to assess Clover Health Investments Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.47
Current PE
-22.30
Overvalued PE
-1.25
Undervalued PE
-17.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
4.82
Current EV/EBITDA
22.53
Overvalued EV/EBITDA
23.89
Undervalued EV/EBITDA
-14.25
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.93
Current PS
0.78
Overvalued PS
2.05
Undervalued PS
-0.18
Financials
Annual
Quarterly
FY2025Q1
YoY :
+33.27%
462.33M
Total Revenue
FY2025Q1
YoY :
-94.30%
-1.27M
Operating Profit
FY2025Q1
YoY :
-94.50%
-1.27M
Net Income after Tax
FY2025Q1
YoY :
-100.00%
0.00
EPS - Diluted
FY2025Q1
YoY :
-149.17%
-16.48M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-133.02%
2.08
FCF Margin - %
FY2025Q1
YoY :
-95.81%
-0.28
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1181.92% over the last month.
Sold
0-3
Months
808.3K
USD
5
3-6
Months
475.5K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
999.6K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.3M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 1181.92% over the last month.
Sold
0-3
Months
808.3K
USD
5
3-6
Months
475.5K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
999.6K
USD
Months
CLOV News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
08:35:24
Clover Health appoints Oldakowski as VP Finance, Controller
2025-07-09 (ET)
2025-07-09
08:40:28
Clover Health launches New Jersey community pharmacy program with IPC
2025-06-30 (ET)
2025-06-30
08:40:10
Clover Health set to join Russell 3000 Index
Sign Up For More Events
Sign Up For More Events
News
4.5
07-24NASDAQ.COMThursday Sector Laggards: Hospital & Medical Practitioners, General Contractors & Builders
3.5
07-22NewsfilterFrom Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
9.5
07-22BenzingaWhy Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
OFG
OFG Bancorp
43.310
USD
+0.93%
PRM
Perimeter Solutions Inc
16.860
USD
+0.42%
ENLT
Enlight Renewable Energy Ltd
25.490
USD
-0.04%
UFPT
UFP Technologies Inc
241.920
USD
+2.47%
OSW
Onespaworld Holdings Ltd
22.210
USD
+0.41%
SLNO
Soleno Therapeutics Inc
86.470
USD
-1.77%
LBTYA
Liberty Global Ltd
10.030
USD
-0.10%
MXL
Maxlinear Inc
16.360
USD
-5.16%
WNS
WNS (Holdings) Ltd
74.720
USD
-0.08%
BTE
Baytex Energy Corp
2.070
USD
-3.27%
FAQ
What is Clover Health Investments Corp (CLOV) stock price today?
The current price of CLOV is 3.035 USD — it has decreased -1.3 % in the last trading day.
What is Clover Health Investments Corp (CLOV)'s business?
What is the price predicton of CLOV Stock?
What is Clover Health Investments Corp (CLOV)'s revenue for the last quarter?
What is Clover Health Investments Corp (CLOV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Clover Health Investments Corp (CLOV)'s fundamentals?
How many employees does Clover Health Investments Corp (CLOV). have?